title: Neuroimaging genetic risk for Alzheimer's disease in preclinical individuals: From candidate genes to polygenic approaches.
abstract: Better characterization of the preclinical phase of Alzheimer's disease (AD) is needed in order to develop effective interventions. Neuropathological changes in AD, including neuronal loss and the formation of proteinaceous deposits, begin up to 20 years before the onset of clinical symptoms. As such, the emergence of cognitive impairment should not be the sole basis used to diagnose AD nor to evaluate individuals for enrollment in clinical trials for preventative AD treatments. Instead, early preclinical biomarkers of disease and genetic risk should be used to determine most likely prognosis and enroll individuals in appropriate clinical trials. Neuroimaging-based biomarkers and genetic analysis together present a powerful system for classifying preclinical pathology in patients. Disease modifying interventions are more likely to produce positive outcomes when administered early in the course of AD. In this review, we examine the utility of the neuroimaging genetics field as it applies to AD and early detection during the preclinical phase. Neuroimaging studies focused on single genetic risk factors are summarized. However, we particularly focus on the recent increased interest in polygenic methods and discuss the benefits and disadvantages of these approaches. We discuss challenges in the neuroimaging genetics field, including limitations of statistical power arising from small effect sizes and the over-use of cross-sectional designs. Despite the limitations, neuroimaging genetics has already begun to influence clinical trial design and will play a major role in the prevention of AD.
authors: Neuroscience Interdepartmental Graduate Program, UCLA, Los Angeles, CA; Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA.
authors: Theresa M
authors: TM
authors: Harrison
authors: Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA; Center for Cognitive Neuroscience, UCLA, Los Angeles, CA.
authors: Susan Y
authors: SY
authors: Bookheimer
keywords: Alzheimer's disease; clinical trials; genetics; neuroimaging; polygenic risk score; preclinical